mRNA-1405

mRNA-1405 is a pentavalent norovirus vaccine candidate developed by Moderna for the prevention of acute gastroenteritis caused by norovirus, particularly targeting young children and older adults. The vaccine utilizes messenger RNA (mRNA) technology to express virus-like particles (VLPs) that mimic native virions and display key antigenic features of the virus. It is administered via intramuscular injection and uses lipid nanoparticle (LNP) delivery technology to facilitate cellular uptake of the mRNA. The multivalent design allows for broad coverage against diverse norovirus genotypes[1][4][8]. As of 2024, mRNA-1405 is in Phase 2 clinical development for this indication[1][3][7].